Scinai Immunotherapeutics
SCNI
3 hedge funds and large institutions have $102K invested in Scinai Immunotherapeutics in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 2 closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
14% less capital invested
Capital invested by funds: $119K → $102K (-$17K)
25% less funds holding
Funds holding: 4 → 3 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EWM
Edge Wealth Management
New York
|
+$36.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$10.9K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VIA
1
Vantage Investment Advisors
State College,
Pennsylvania
| $57K | – | – | – |
|
|
2
Bank of Montreal
Toronto,
Ontario, Canada
| $44K | -$10.9K | -30 | -20% |
|
|
EWM
3
Edge Wealth Management
New York
| $1K | +$36.3K | +100 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| – | -$2K | -5 | Closed |
|
SCNI Hedge Fund Activity: Q4 2016 in Review
3 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q4 2016, worth a combined $102K — down 14% from $119K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of SCNI and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest buyer was Edge Wealth Management, opening a new position worth an estimated $36.3K. The largest seller was Bank of Montreal, cutting an estimated $10.9K.
- 3 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q4 2016, down from 4 in Q3 2016.
- Funds reported $102K of Scinai Immunotherapeutics stock for Q4 2016, down 14% quarter-over-quarter.
- 1 fund opened new Scinai Immunotherapeutics positions in Q4 2016 and 2 closed out, a net change of -1 holder.
- The largest Scinai Immunotherapeutics buyer in Q4 2016 was Edge Wealth Management, an estimated $36.3K added.
- The largest Scinai Immunotherapeutics seller in Q4 2016 was Bank of Montreal, an estimated $10.9K sold.
Based on aggregated 13F filings for Q4 2016.